Keith Orford
Chief Medical Officer at Parabilis Medicines
Professional Overview
Keith Orford is an accomplished physician-scientist with extensive experience in clinical development and immuno-oncology. As the Chief Medical Officer at Parabilis Medicines, he oversees the company's medical strategy and leads cross-functional teams in advancing novel therapeutic candidates through the clinical pipeline.
Experience Summary
Current Role
As Chief Medical Officer at Parabilis Medicines, Keith is responsible for directing the overall medical and clinical strategy for the company's pipeline of innovative oncology and immunology therapies. He leads a team of clinicians and researchers in designing and executing robust clinical trial programs, ensuring alignment with regulatory requirements. Under his leadership, Parabilis has advanced several promising drug candidates into late-stage clinical development, demonstrating the potential to significantly improve patient outcomes.
Keith also serves on the Board of Directors at Calithera Biosciences, providing strategic guidance on the company's clinical development initiatives. Concurrently, he holds the position of Clinical Development Lead for Immuno-Oncology and Combinations at GlaxoSmithKline, where he oversees the advancement of combination therapies that harness the power of the immune system to fight cancer.
Career Progression
Prior to his current roles, Keith held the position of Associate Director of Clinical Pharmacology and Experimental Medicine/Oncology at Merck, where he played a key role in the development of several oncology and immunology products. He began his career as an Assistant in Biology at Massachusetts General Hospital, where he conducted groundbreaking research on novel cancer immunotherapies.
Throughout his career, Keith has garnered a reputation as a respected thought leader in the field of immuno-oncology, contributing to the advancement of the field through his clinical expertise and scientific insights. His work has been widely published in peer-reviewed journals, and he has been invited to speak at numerous industry conferences and events.
Academic Background
Keith holds a medical degree from Harvard Medical School, where he specialized in oncology and immunology. He completed his residency and fellowship training at leading academic institutions, gaining extensive expertise in the clinical management of complex cancer patients.
Areas of Expertise
- Oncology and Immuno-Oncology
- Clinical Development and Trial Design
- Combination Therapy Strategies
- Regulatory Compliance and Approval Pathways
- Cross-Functional Team Leadership and Collaboration
Professional Impact
Under Keith's leadership, Parabilis Medicines has advanced several promising oncology and immunology candidates into late-stage clinical trials, with the potential to significantly improve patient outcomes. His work has been instrumental in driving the development of novel combination therapies that harness the power of the immune system to fight cancer.
Conclusion
With his deep understanding of the clinical and scientific landscape, combined with his proven track record of success in the biopharmaceutical industry, Keith Orford is a highly respected and influential figure in the field of immuno-oncology. As Chief Medical Officer at Parabilis Medicines, he continues to drive innovation and push the boundaries of what is possible in the treatment of cancer and other complex diseases.
